Cargando…

Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting

Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for patients with the 2019 coronavirus (COVID-19). However, little is known about their effectiveness in older adults and those at high risk of disease progression. This retrospective single-center observatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Mutoh, Yoshikazu, Umemura, Takumi, Nishikawa, Takeshi, Kondo, Kaho, Nishina, Yuta, Soejima, Kazuaki, Noguchi, Yoichiro, Bando, Tomohiro, Ota, Sho, Shimahara, Tatsuki, Hirota, Shuko, Hagimoto, Satoshi, Takei, Reoto, Fukihara, Jun, Sasano, Hajime, Yamano, Yasuhiko, Yokoyama, Toshiki, Kataoka, Kensuke, Matsuda, Toshiaki, Kimura, Tomoki, Ichihara, Toshihiko, Kondoh, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054616/
https://www.ncbi.nlm.nih.gov/pubmed/36992519
http://dx.doi.org/10.3390/v15030811
Descripción
Sumario:Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for patients with the 2019 coronavirus (COVID-19). However, little is known about their effectiveness in older adults and those at high risk of disease progression. This retrospective single-center observational study assessed and compared the outcomes of COVID-19 treated with MOV and NMV/r in a real-world community setting. We included patients with confirmed COVID-19 combined with one or more risk factors for disease progression from June to October 2022. Of 283 patients, 79.9% received MOV and 20.1% NMV/r. The mean patient age was 71.7 years, 56.5% were men, and 71.7% had received ≥3 doses of vaccine. COVID-19-related hospitalization (2.8% and 3.5%, respectively; p = 0.978) or death (0.4% and 3.5%, respectively; p = 0.104) did not differ significantly between the MOV and NMV/r groups. The incidence of adverse events was 2.7% and 5.3%, and the incidence of treatment discontinuation was 2.7% and 5.3% in the MOV and NMV/r groups, respectively. The real-world effectiveness of MOV and NMV/r was similar among older adults and those at high risk of disease progression. The incidence of hospitalization or death was low.